Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good morning, Dorsey:
Sounds like you're getting up - me, in CA finally ready to turn in. Up later than usual. 2:42 a.m. here.
Have a great Dorsey!
Ann
Sorry:
Ancestry e-Symposium - Tony Frudakis - speaker, etc.
Ann
Ancestry by DNA Symposium:
http://www.ancestry.e-symposium.com/programme.php
Ann
You can also scroll the wheel of your mouse over any sentence or word as it gets new information up and the presentations and topics go on and on...
Ann
Please examine "every aspect" of this power-point '06 Shareholder meeting Presentation. (every click of the mouse on any topic, presents a result):
http://www.dnaprint.com/welcome/pps/share_holder_metting_2006.pps#503,1,WELCOME%20%20to%20the%20%20%...
Ann
BIofrontera Preparing for List on Prime Standard
(German version only available) - any translators? - Machine kaput? - lol
http://www.hd-innovation.de/en/presse/?id=102&sid=2c6c9cba097880cabf4f4626ee1ec6bd
Ann
You Go, Stockhldr!
Take care,
Ann
wrl:
Dr. Fru uses "subliminal" negatives, such as referring to DNAP as a "pig" - and then ends his dissertations by courtly phrases and respectul innuances. Just read and "dissect" his posts. That's Fru for you - Fru & Fru.
Take care,
Ann
wrl:
OT:
"I have heard that Frudaky is in Washington"
So glad he's on our side.
Take care,
Ann
Stockhldr:
I'm finaly calling it a day. All the best to you and your endeavors...I know you are able, willing and ready for IPO updates, if/when/as they occur...best of luck to you and all DNAPers!
Take care,
Ann
Stock:
Since I'm a night owl - will probably be up for a few more...
Take care,
Ann
"You're a caution!" Stockhldr...
Hope you realize your perceived/set goals...Hey, what did happen to Dr. Frudaky? Is he/she vegetating through all this guesswork at hand?
Take care,
Ann
2006 Annual Shareholder Meeting presentation posted on DNAP website:
http://www.dnaprint.com/welcome/pps/share_holder_metting_2006.pps
Ann
OT:
"Dr. fru" is all loaded up..."
I hear he's in a summit w/N. Korea on how to send one of their rockets to the moon! - lol
But ay...
Ann
BTW -
Where is Dr. Fru? Curious. (Probably shouldn't wake him - lol)
Ann
1/06 news release of IPO:
http://www.sciencebusiness.net/latest_news/item6.php
Ann
Take a look at Biofrontera Supervisory Board & Investors:
(Stockhldr - just providing a look):
http://www.biofrontera.com/cms/index.php?id=7
Ann
Just found out - AOL using Ancestry.com
Ann
Posted on the AOL News section tonight - I wonder whose geneology tests these are? Guides you to a test registration form.
"We're all related to Royalty" - Brooke Shields involved.
http://articles.news.aol.com/news/_a/genealogists-discover-royal-roots-for/20060701201109990001?cid=...
Ann
Not being a stock professional, can anyone else figure what the following means. I only listed DNAP - there are other companies on the list - (document dated: 4/06):
SECURITIES ACT REGISTRATIONS
The following registration statements have been filed with the SEC under the Securities Act of 1933. The reported information appears as follows: Form, Name, Address and Phone Number (if available)of the issuer of the security; Title and the number and/or face amount of the securities being offered; Name of the managing underwriter or depositor (if applicable); File number and date filed; Assigned
Branch; and a designation if the statement is a New Issue.
Registration statements may be obtained in person or by writing to the Commission's Public Reference Branch at 450 Fifth Street, N.W., Washington, D.C. 20549 or at the following e-mail box address:
<publicinfo@sec.gov>. In most cases, this information is also available on the Commission's website: <www.sec.gov>.
SB-2 DNAPRINT GENOMICS INC, 900 COCONUT AVE., SARASOTA, FL, 34231,
9413663400 - 600,000,000 ($13,200,000.00) Equity, (File 333-133168 -
Apr. 10) (BR. 01A)
Just curious,
Ann
Stockhlder:
I knew you would dissect it well - lol
Take care,
Ann
Scheduling speakers on Ancestry E-Symposium:
Additional info, also to peruse
http://www.ancestry.e-symposium.com/programme.php
Ann
So sorry to hear that FSAIL.
Bless you through your hardships and take care the best you can,
Ann
TU - TEAM - like your card much better. Had no time to look for something more classy than mine...but, in this case, it's the thought that counts! - lol
Later,
Ann
Ming0's post on IV and his comment (last paragraph):
DNAPrint names new CFO
Tampa Bay Business Journal - 10:26 AM EDT Thursday
DNAPrint Genomics Inc. appointed Karen Surplus as chief financial officer, effective immediately.
Monica Tamborini, who has been chief financial officer and chief operating officer since May 2003, is retiring, according to a release.
The company is conducting a search for a new chief operating officer, according to a spokesman.
Surplus is a certified public accountant who has operated her own financial consulting business for the past three years.
Previously, she was chief financial officer of Digital Fusion Inc. (OTC BB: DIGF), based in Huntsville, Ala.; chief accounting officer at Tampa-based PowerCerv Corp.; and controller and treasurer of Progress Credit Corp., a subsidiary of Progress Energy (NYSE: PGN).
DNAPrint Genomics (OTC BB: DNAG), based in Sarasota, develops genomics-based products and services.
So, they have decided to split the CFO and COO roles, which is usually indicative of a company reaching a size where this is warranted and the two roles being too big for one indivudual to handle.
Ann
Happy 4th everyone!
http://www.icq.com/friendship/pages/browse_page_7785.php
Ann
Score 1 for DNAP:
http://moneyextra.uk-wire.com/cgi-bin/articles/20040428210700NZ277.html
Ann
Substantiating DNAP's factual verification of Yang:
"To project this to DNAPrint – what would be needed for accurate analysis of actual direct ancestry are more AIMs, more powerful algorithms, and – very important – more and more varied parental populations to determine the allele frequencies. And the authors of the Yang study seem to understand that the same limitations apply to their work. However, the data in both cases are perfectly sound in getting a solid view of the relative, comparative genetic (“ancestral”) components of different groups, and thus to “bin” individuals into different clusters of major groups, as well as the identification of admixture within groups and individuals.
In both cases – Yang and DNAPrint – “blind” studies of individuals correctly identify majority race with ~ 100% accuracy, as well as identify, in many cases, significant admixture consistent with known population histories and with individual phenotypes. The point being, in the last analysis, is that while a more perfect analysis would be able to detect “true ancestry” and complete “population diversity” (including Australian aboriginals, Papuans, etc.), the more limited set of AIMs and parental populations are currently sufficient to identify major racial and sub-racial populations, and admixture of these, by observing the patterns of genetic components characteristic of each group.
Thus, even if DNAPrint (or Yang et al) would label the different clusters as A,B,C, D and NOT with actual names of population groups, and even if we did not know the exact origin of these genetic components, we could say, for example, that North Europeans are characterized by, typically, a profile of proportions 6A, 2B, 1C, and 1D, while Southern Europeans were 3A, 4B, 2C, and 1D, and Middle Easterners were 0A, 1B, 6C, and 2D, etc.
In any case, in summary:-
Race is real. And South Asians are a different race than Europeans. And the results of the Yang paper are generally consistent with the broad outlines of the racial and sub-racial DNAPrint data.
Ann
DNAP's business model:
TWST: What about the pharmaceutical prospects?
Mr. Gabriel: While we see our forensics business as an engine that will generate revenues for the company, one of our fundamental goals is to apply this technology to drug development. We recently took a big step in that direction by acquiring an exclusive worldwide license from Harvard Medical School's Beth Israel Deaconess Medical Center (BIDMC).
This is a royalty bearing agreement that creates an opportunity for DNAPrint genomics to develop a new, more potent and longer acting form of the anemia drug Erythropoietin (EPO). EPO is currently commercialized by Amgen, Johnson & Johnson and Roche in a worldwide market that exceeds $10 billion and that has been growing at an average annual rate of 21%. The human gene that produces EPO was cloned in 1985 and in 1989, scientists at Amgen introduced to market a recombinant form under the trade name EPOGEN', a drug that many credit for the rise of Amgen in the
1990s as one of the world's most successful biotechnology companies ever. Erythropoietin has been approved by the Food and Drug Administration as a treatment for anemia associated with renal failure, cancer chemotherapy, and Zidovudine-treated HIV-infected patients and to reduce blood transfusion in surgery patients. Our goal is to develop and market a 'super'-EPO, a more powerful form of the drug. This is a perfect fit within the company's overarching strategy to utilize recent genomics and chemistry advances made by our researchers to develop next-
generation drugs that maximize efficacy and minimize side effects by tailoring medication for specific individuals and well-defined population sectors. In addition, we already have developed a product called OVANOME_ in collaboration with the University of Florida and the H. Lee Moffitt Cancer Center. OVANOME is a genomic-based diagnostic tool for matching ovarian cancer patients with the most suitable form and dose of chemotherapy. We're particularly concentrating on patients being
treated with the drug Taxol. In previous FDA trials, Taxol-Carboplatin drug combination therapy demonstrated efficacy in only about 60% of patients treated. Our OVANOME therapeutic response tests have yielded encouraging results so far. They were 96% effective in distinguishing Taxol-Carboplatin responders from non-responders. Obviously, you do not want to give a chemotherapeutic agent to a person unless you're going to
get a positive response. We've been collecting samples all along, but we just now are in the process of enrolling an additional 100 patients into a trial at the Moffitt Center, and over the next six to nine months we'll be finalizing the data. Our goal is to be able to go to the FDA and show them how important genetic ancestry is. When we originally looked at the data on a prospective basis of patient populations, we
couldn't make sense of it. That's part of the problem with gene data, no matter what technology you are using. If you don't understand the ancestry, or the genetic inheritance that goes along with that data, it's very difficult puzzle to solve because hundreds and hundreds of genes need to be analyzed. We're not claiming that we have the end-all- and-be-all answer, but we certainly have what we think is a reasonable tool for analyzing that very complex data. The second product in our
pipeline is STATINOME_. This is a test for the cardiac drug market to determine whether patients will be good or poor responders to a class of drugs called statins. The importance here is that statins are effective in cholesterol reduction but adverse reaction can lead to liver damage or kidney failure.
Ann
This is DNAP's:
http://www.familytreemagazine.com/articles/dec03/legends.html
Ann
DNAPrint & NHI Grant:
http://www.dnaphenomics.com/pressrelease1-31-05.php
Ann
Bellweather Report on DNAP:
http://www.stockhouse.com/news/news.asp?tick=DNAG&newsid=3759158
Ann
Altar:
"Although I should be to lend the religious support we'll all going to be needing."
I'll be clicking MY beads - lol!
Ann
Team - Dad:
OT:
Sorry I didn't send you a card - lol
Good to hear from you - we've been in this stock many years now...but, I want to know what Columbus felt like when he saw land!
Have a great one!
Ann
Michiko:
Whatever that means...(you'll have to explain that one to me - lol)
I'm having a busy day - and hardly ever sit around glued to the TV - occasionally to this board - back later.
Sayonara,
Ann
Arch & all you Dads out there:
"Happy Father's Day!
Take care,
Ann
For Stock101's info:
"The Company also recently expanded its ownership into a German Specialty Pharmaceutical company called Biofrontera AG. Biofrontera recently raised 20 Million Euros in a Bond placement that is openly being traded on the Frankfurt exchange. The opening price of the bond was 100 Euros per bond with an 8% coupon. The bond is fully converted at an IPO and there are 6.2 common shares per bond. DNAPrint holds 455,179 shares of Biofrontera or nearly 18% of the outstanding shares on a fully diluted basis. The bond price translates to 16.13 Euros per share."
For whatever it's worth...Ann
Market Wire & DNAP:
http://www.marketwire.com/mw/frame_multimedia?prid=132263&attachid=274885
Ann
Market Pulse & DNAP:
http://www.market-pulse.com/dnagprofile2.htm
Ann
Good exposure & publicity:
http://www.rense.com/general66/suspects.htm
Ann